Kazia Therapeutics Limited has announced the filing of its Annual Report on Form 20-F for the fiscal year ended June 30, 2026. This filing is significant as it provides insights into the company’s financial health and clinical advancements in oncology.
Based in Sydney, Australia, Kazia Therapeutics is an oncology-focused biotechnology company that develops therapies aimed at reprogramming cancer biology. The company operates under the Standard Industrial Classification of Pharmaceutical Preparations (SIC 2834) and is listed on the Nasdaq under the ticker KZIA. Recent filings include a 20-F on November 17, 2026, and a Schedule 13G on November 16, 2026.
The filing reveals that Kazia has approximately A$61.2 million in cash, cash equivalents, and short-term investments as of June 30, 2026. The company believes this financial position, along with proceeds from a public offering and a milestone payment, is sufficient to fund its operations for at least the next 12 months. The report also highlights a 100% clinical benefit rate and an 83% objective response rate in initial data from a Stage IV triple-negative breast cancer trial.
This update may impact shareholders and potential investors, as it provides a clearer picture of Kazia's financial stability and ongoing clinical trials. The filing indicates that the company is well-positioned to continue its research and development efforts, particularly with its lead asset, paxalisib, which has received multiple designations from the U.S. FDA.
Looking ahead, Kazia is expected to continue its focus on clinical trials, including a planned expansion into additional indications for breast cancer and colorectal cancer. The filing does not specify the next steps but emphasizes the company’s commitment to advancing its pipeline of oncology therapies.
Read Next
Q/C Technologies Enters Omnibus Amendment Agreement
ONE Nuclear Energy settles consulting fees with stock issuance
HCW Biologics delays stockholder vote amid quorum issues
bioAffinity Technologies amends share structure in 8-K filing
VisionWave amends sponsorship deal with Hen Basketball Haifa Club
Apimeds Pharmaceuticals Amends Agreement with FreeT Inc.










